On the stock market since 2009, it operates in the world of health and science. It has 4,541 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
No real growth (3% a year). Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
An investor who bought at the very peak is down 69% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
It pays out $0.26 per share each year — regular cash for whoever holds the stock.
A loss of $509.7M against $16.4B in annual sales. And on top of that, sales fell from the year before.
Since the drop from its peak, buyer appetite hasn’t come back.
On our five-subject report card, EKTAY sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: EKTAY has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.